News, Events, and Updates

News 02/05/2014

Amgen And Merck Announce Collaboration To Evaluate Investigational Combination Treatment For Advanced Melanoma

Amgen and Merck announced today that they have entered into an agreement through a subsidiary to evaluate the safety and efficacy of talimogene laherparepvec, an investigational oncolytic immunotherapy, combined with MK-3475, an investigational anti-PD-1 immunotherapy, in a Phase 1b/2 study of patients with mid- to late-stage melanoma. February 5, 2014

News 02/04/2014

Marker May Predict Response to Ipilimumab in Advanced Melanoma

Among patients with advanced melanoma, presence of higher levels of the protein vascular endothelial growth factor (VEGF) in blood was associated with poor response to treatment with the immunotherapy ipilimumab, according to a study. February 4, 2013

News 01/06/2014

Immune Profile of Lymph Nodes Nearest to Tumor May Predict Melanoma Progression

Melanoma patients who had a specific subtype of immune cells called CD30-positive T cells in the lymph nodes closest to their tumors were more likely to have their disease progress within five years, according to data published in Cancer Research, a journal of the American Association for Cancer Research. January 6, 2014

News 01/05/2014

Blood Test Reveal Skin Cancer Spread

A simple blood test could be used to identify patients whose melanoma - the most serious form of skin cancer - has started to spread to other parts of the body, according to research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool. January 5, 2014

Please keep me informed.

Receive comprehensive, breaking news about melanoma, research, legislation, and events.

  • This field is for validation purposes and should be left unchanged.